Ranitidine

Generic Name: Ranitidine

Brand Names: Good Sense Acid Reducer, Wal-zan, Zantac

Drug Type: Small Molecule

Chemical Formula: C_₁₃H_₂₂N_₄O_₃S

CAS Number: 66357-35-5

Unique Ingredient Identifier: 884KT10YB7

Background: Ranitidine is a commonly used drug, classified as a histamine H2-receptor antagonist, and belongs to the same drug class as cimetidine and famotidine. This drug helps to prevent and treat gastric-acid associated conditions, including ulcers, because of its ability to decrease gastric acid secretion. Ranitidine is often referred to as Zantac, and is available...

Indication: This drug is used alone or with concomitant antacids for the following conditions: short-term treatment of active duodenal ulcer, treating gastric acid hypersecretion due to Zollinger-Ellison syndrome, systemic mastocytosis, and other conditions that may pathologically raise gastric acid levels. It also used in the short term treatment of active benign gastr...

Associated Conditions: Acid Aspiration Syndrome, Ankylosing Spondylitis (AS), Duodenal Ulcer, Erosive Esophagitis, Gastric Ulcer, Gastric hypersecretion, Gastro-esophageal Reflux Disease (GERD), Healing, Heartburn, Osteoarthritis (OA), Peptic Ulcer Disease, Rheumatoid Arthritis, Stress Ulcers, Zollinger-Ellison Syndrome, Active Duodenal ulcer, Benign gastric ulcer healing, Benign gastric ulcers, Duodenal ulcer healing, Post-operative peptic ulcer, Recurrent hemorrhage from bleeding ulcers

Associated Therapies: -

Clinical Trials

Study of H2 Antagonist and a Proton Pump Inhibitor of Selpercatinib in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Selpercatinib
Drug: Ranitidine
Drug: Omeprazole

First Posted Date: 2022-04-21

Last Posted Date: 2024-10-30

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 20

Registration Number: NCT05338502

Locations: 🇺🇸
Covance Clinical Research Unit, Inc., Madison, Wisconsin, United States

Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel

Phase 2

Completed

Conditions: Anatomic Stage I Breast Cancer AJCC v8
Prognostic Stage IIIA Breast Cancer AJCC v8
Prognostic Stage IV Breast Cancer AJCC v8
Anatomic Stage 0 Breast Cancer AJCC v8
Anatomic Stage IA Breast Cancer AJCC v8
Anatomic Stage IB Breast Cancer AJCC v8
Anatomic Stage II Breast Cancer AJCC v8
Anatomic Stage IIA Breast Cancer AJCC v8
Anatomic Stage IIB Breast Cancer AJCC v8
Anatomic Stage III Breast Cancer AJCC v8

Interventions: Drug: Cimetidine
Drug: Dexamethasone
Drug: Diphenhydramine
Drug: Famotidine
Drug: Paclitaxel
Other: Quality-of-Life Assessment
Drug: Ranitidine

First Posted Date: 2021-04-28

Last Posted Date: 2024-08-09

Lead Sponsor: Ohio State University Comprehensive Cancer Center

Target Recruit Count: 129

Registration Number: NCT04862585

Locations: 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies

Phase 1

Active, not recruiting

Conditions: Recurrent Acute Leukemia
Recurrent B Acute Lymphoblastic Leukemia
Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm
Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Refractory Hairy Cell Leukemia
Refractory Hematologic Malignancy
Refractory Hodgkin Lymphoma
Refractory T Acute Lymphoblastic Leukemia
Systemic Mastocytosis

Interventions: Drug: Acetaminophen
Drug: Dexamethasone
Drug: Diphenhydramine
Biological: Flotetuzumab
Drug: Ibuprofen
Drug: Ranitidine

First Posted Date: 2020-12-23

Last Posted Date: 2023-12-20

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 13

Registration Number: NCT04681105

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States

Clinical Study to Investigate the Urinary Excretion of N-nitrosodimethylamine (NDMA) After Ranitidine Administration

Phase 1

Completed

Conditions: Ranitidine Adverse Reaction
Food-drug Interaction
Pharmacokinetics

Interventions: Drug: Placebo
Drug: Ranitidine
Other: Low nitrite/NDMA meals
Other: High nitrite/NDMA meals

First Posted Date: 2020-05-21

Last Posted Date: 2021-08-09

Lead Sponsor: Food and Drug Administration (FDA)

Target Recruit Count: 18

Registration Number: NCT04397445

Locations: 🇺🇸
Spaulding Clinical Research, West Bend, Wisconsin, United States

A Crossover Study to Assess the Drug-drug Interaction of Acid Reducing Agent(s) on the Pharmacokinetics of a Single Oral Dose of Lumicitabine (JNJ-64041575) in Healthy Adult Participants

Phase 1

Terminated

Conditions: Healthy

Interventions: Drug: Lumicitabine
Drug: Lansoprazole
Drug: Ranitidine

First Posted Date: 2018-03-19

Last Posted Date: 2018-07-23

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 18

Registration Number: NCT03468777

Locations: 🇧🇪
Clinical Pharmacology Unit, Merksem, Belgium

A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT

Phase 3

Active, not recruiting

Conditions: Multiple Sclerosis

Interventions: Drug: Alemtuzumab GZ402673
Drug: Glatiramer acetate
Drug: Beta-Interferon
Drug: Methylprednisolone
Drug: Ranitidine
Drug: Ceterizine
Drug: Dexchlorpheniramine
Drug: Paracetamol
Drug: Acyclovir
Drug: Prednisolone
Drug: Diphenydramine
Drug: Other H1 antagonist

First Posted Date: 2017-12-11

Last Posted Date: 2023-09-21

Lead Sponsor: Genzyme, a Sanofi Company

Target Recruit Count: 16

Registration Number: NCT03368664

Locations: 🇹🇷
Investigational Site Number :7920002, Ankara, Turkey
🇹🇷
Investigational Site Number :7920001, Ankara, Turkey
🇫🇷
Investigational Site Number :2500002, Strasbourg, France

and more 18 locations

Histamine Receptor 2 Antagonists as Enhancers of Anti-Tumour Immunity

Phase 4

Completed

Conditions: Cancer

Interventions: Drug: Ranitidine

First Posted Date: 2017-05-09

Last Posted Date: 2023-02-08

Lead Sponsor: Nova Scotia Health Authority

Target Recruit Count: 30

Registration Number: NCT03145012

Locations: 🇨🇦
Nova Scotia Health Authority, Halifax, Nova Scotia, Canada

Safety and Efficacy of Isatuximab in Lymphoblastic Leukemia

Phase 2

Terminated

Conditions: T-lymphoblastic Lymphoma/Leukaemia
T-cell Type Acute Leukemia-Precursor

Interventions: Drug: Isatuximab SAR650984
Drug: dexamethasone
Drug: acetaminophen
Drug: ranitidine
Drug: diphenhydramine

First Posted Date: 2016-12-21

Last Posted Date: 2022-03-21

Lead Sponsor: Sanofi

Target Recruit Count: 14

Registration Number: NCT02999633

Locations: 🇺🇸
Investigational Site Number 8400001, Houston, Texas, United States
🇺🇸
Investigational Site Number 8400002, Atlanta, Georgia, United States
🇫🇮
Investigational Site Number 2460001, Helsinki, Finland

and more 14 locations